More info
Active ingredients
Trimebutin
Release form
Pills
Composition
Trimebutin maleate 100 mg. Auxiliary substances: lactose, colloidal silicon dioxide, talc, corn starch, magnesium stearate.
Pharmacological effect
Trimebutin, acting on the enkephalinergic system of the intestine, is a regulator of its peristalsis. Possessing an affinity for receptors of excitation and suppression, it has a stimulating effect in hypokinetic states of the smooth muscles of the intestine and antispasmodic in hyperkinetic conditions. The drug acts throughout the gastrointestinal tract, reduces the pressure of the esophageal sphincter, promotes gastric emptying and increases intestinal motility, and also contributes to the response of the smooth muscles of the colon to food stimuli. Trimebutin restores the normal physiological activity of the muscles of the intestine in various diseases of the gastrointestinal tract associated with impaired motility.
Pharmacokinetics
After ingestion, trimebutin is rapidly absorbed from the gastrointestinal tract. Tmax in blood plasma - 1–2 hours. Bioavailability is 4–6%. Vd - 88 l. The degree of plasma protein binding is low - about 5%. Trimebutin to a small extent penetrates the placental barrier. Metabolism and excretion. Trimebutin is biotransformed in the liver and excreted in the urine mainly as metabolites (approximately 70% during the first 24 hours). T1 / 2 - about 12 hours
Indications
- Motor disorders in functional diseases of the gastrointestinal tract, gastroesophageal reflux disease, dyspepsia disorders in gastroduodenal diseases (abdominal pain, digestive disorders, nausea, vomiting), irritable bowel syndrome (functional disease of the gastrointestinal tract, manifested, in particular, pain and colic in the abdominal cavity, intestinal cramps, flatulence, diarrhea and / or constipation) .- Postoperative paralytic intestinal obstruction, preparation for a radiologist aesthetic and endoscopic studies of the gastrointestinal tract. Use in children: dyspeptic disorders associated with impaired motility of the gastrointestinal tract.
Contraindications
Hypersensitivity to the components that make up the drug. Children up to 3 years old - for this dosage form.
Use during pregnancy and lactation
It is not recommended to use the drug in the first trimester of pregnancy and lactation. The use of the drug Trimedat during breastfeeding due to the lack of reliable clinical data confirming the safety of the drug is not recommended. In experimental studies there were no data on the teratogenicity and embryotoxicity of the drug.
Dosage and administration
Inside Adults and children from 12 years: 100-200 mg 3 times a day. To prevent the recurrence of irritable bowel syndrome after a course of treatment during remission, it is recommended to continue taking the drug at a dose of 300 mg per day for 12 weeks. Children 3-5 years: 25 mg three times a day. Children 5-12 years: 50 mg three times a day.
Side effects
Seldom: skin reactions
Overdose
To date, cases of overdose Trimedat® not reported
Interaction with other drugs
Drug interaction drug Trimedat not described
special instructions
The course of treatment of irritable bowel syndrome in the acute period of 600 mg per day for 4 weeks and the continuation of treatment after the course at a dose of 300 mg per day for 12 weeks avoids the recurrence of the disease.